---
title: "MiMedx Group, Inc. (MDXG.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MDXG.US/overview.md"
symbol: "MDXG.US"
name: "MiMedx Group, Inc."
parent: "https://longbridge.com/en/quote/MDXG.US.md"
datetime: "2026-04-17T06:37:25.258Z"
locales:
  - [en](https://longbridge.com/en/quote/MDXG.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MDXG.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MDXG.US/overview.md)
---

# MiMedx Group, Inc. (MDXG.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 1775 West Oak Commons Court, NE, Marietta, Georgia, United States |
| Website | [www.mimedx.com](https://www.mimedx.com) |

## Company Profile

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.

## Key Executives

| Name | Title |
|------|-------|
| Joseph H. Capper | CEO & Director |
| Douglas C. Rice | Chief Financial Officer |
| Ricci S. Whitlow | Executive VP & COO |
| William F. Hulse | General Counsel & Chief Administrative Officer |
| Kimberly Maersk-Moller | Chief Commercial Officer |
| K. Todd Newton | Independent Director |
| James L. Bierman | Independent Director |
| William A. Hawkins | Independent Preferred Director |
| Martin Paul Sutter | Independent Preferred Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Essex Woodlands Management, Inc. | 18.98% | 2025-12-31 |
| BlackRock, Inc. | 7.63% | 2025-12-31 |
| The Vanguard Group, Inc. | 4.84% | 2025-12-31 |
| Trigran Investments, Inc. | 4.15% | 2025-12-31 |
| State Street Global Advisors, Inc. | 2.57% | 2025-12-31 |
| First Light Asset Management, LLC | 2.05% | 2025-12-31 |
| Geode Capital Management, LLC | 1.91% | 2025-12-31 |
| Dimensional Fund Advisors LP | 1.67% | 2025-12-31 |
| Renaissance Technologies LLC | 1.66% | 2025-12-31 |
| Paradigm Capital Management, Inc. | 1.65% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Biotechnology (startups) | 418630000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "MiMedx Group, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Biotechnology (startups)",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 418630000 | 100% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**